GlassScriptPhysician profile
Victoria Eng
NPI 1730573015
$5,122.71
in general payments reported to CMS, 2019-2025
26 companies · $41.03 in 2025
The $41.03 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.24 · 2021: $781 · 2022: $1,550 · 2023: $1,169 · 2024: $1,504 · 2025: $41.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $814.81 | 2021-2024 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $702.36 | 2021-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $637.55 | 2021-2024 | Dupixent |
| Genzyme Corporation | $394.84 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.67 | 2020-2024 | Takhzyro, Eohilia, Cuvitru |
| Pharming Healthcare, INC. | $263.97 | 2021-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $221.30 | 2023-2024 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.65 | 2020-2022 | |
| Grifols USA, LLC | $200.62 | 2020-2022 | |
| Csl Behring | $196.42 | 2021-2024 | Hizentra, Haegarda |
| Incyte Corporation | $177.22 | 2021-2022 | |
| Optinose US, INC. | $161.31 | 2022-2023 | |
| Blueprint Medicines Corporation | $125.00 | 2024 | |
| Amgen INC. | $110.57 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $99.39 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $89.87 | 2022-2023 | Coagadex, Gammaplex |
| Pfizer INC. | $79.97 | 2021 | |
| Genentech USA, INC. | $72.79 | 2021-2022 | |
| Covis Pharma Gmbh | $51.18 | 2022-2023 | |
| Alk-Abello, INC | $49.70 | 2023 | Odactra |
| Aimmune Therapeutics, INC. | $37.66 | 2021-2023 | |
| Greer Laboratories, INC. | $32.24 | 2024 | Palforzia |
| Kaleo, INC. | $28.25 | 2022-2023 | Auvi-Q |
| Leo Pharma INC. | $27.36 | 2022 | |
| Organon LLC | $16.54 | 2025 | |
| Octapharma USA, INC. | $15.47 | 2023 | Cutaquig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.